Lake Street raised the firm’s price target on Coya Therapeutics (COYA) to $17 from $16 and keeps a Buy rating on the shares after the company released preclinical in vivo neuroinflammation data for COYA-303 consistent with earlier in vitro preclinical results released by Coya.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Coya Therapeutics announces results from COYA 303 in vivo animal study
- Coya Therapeutics’ Promising ALS Study: A Potential Game-Changer?
- Coya Therapeutics Announces Public Offering of Shares
- Coya Therapeutics 3.64M Spot Secondary priced at $5.50
- Coya Therapeutics announces common stock offering, no amount given